deucravacitinib – Talk Bio

J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

1 month ago talkbio0Tagged Dental Plaque, deucravacitinib, IL-23 receptor antagonist, JNJ-2113, Johnson & Johnson, Myers, oral peptide, Phase 3 clinical trial, Psoriasis, skin clearance, Sotyktu

Icotrokinra; JNJ-2113; Johnson & Johnson; IL-23 receptor antagonist; Sotyktu; deucravacitinib; plaque psoriasis; Phase 3 clinical trial; skin clearance; oral peptide; Bristol Myers Squibb

Sotyktu Shows Promise in Phase 3 Psoriatic Arthritis Trial

8 months ago talkbio0Tagged Arthritis, Psoriatic, deucravacitinib, Inhibitor, Myers, POETYK, PsA-2 trial, Sotyktu, squibb, TYK2 gene

Sotyktu, deucravacitinib, psoriatic arthritis, Bristol Myers Squibb, POETYK PsA-2 trial, TYK2 inhibitor

Sotyktu Expands Potential with Successful Phase III Trials in Psoriatic Arthritis

10 months ago talkbio0Tagged Arthritis, Psoriatic, deucravacitinib, Inhibitor, Myers, Phase 3 Clinical Trials, Sotyktu, squibb, TYK2 gene

Sotyktu, deucravacitinib, psoriatic arthritis, Phase III trials, Bristol Myers Squibb, TYK2 inhibitor